• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Tactile Medical Announces New Appointments to Board of Directors

    1/5/22 4:05:00 PM ET
    $JNJ
    $ORCL
    $PHG
    $TCMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Computer Software: Prepackaged Software
    Technology
    Get the next $JNJ alert in real time by email

    MINNEAPOLIS, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical") (NASDAQ:TCMD), a medical technology company focused on developing medical devices for the treatment of patients with underserved chronic diseases at home, today announced the appointment of Valerie L. Asbury and D. Brent Shafer to the Company's Board of Directors ("Board"), effective January 5, 2022. Ms. Asbury will serve as a member of both the Audit Committee and the Compliance & Reimbursement Committee. Mr. Shafer will serve as a member of the Audit Committee, the Compensation & Organization Committee, and the Nominating & Corporate Governance Committee. Three long-standing directors will be retiring from the Board ahead of the May shareholder meeting: Peter Soderberg, Richard Nigon and Kevin Roche.

    "We are extremely pleased to welcome Valerie and Brent to our Board; both experienced leaders, adding depth of expertise in the treatment of chronically ill patients and channels to access and support them," said Bill Burke, Chairman of the Board of Tactile Medical. "I would also like to extend my sincere gratitude to Peter, Dick and Kevin for their dedicated years of service. Their counsel and oversight played an important role in helping Tactile Medical become a successful company, eclipsing $200 million in annual revenue."

    Since 2018, Valerie Asbury has served as the President and CEO of LifeScan, a global leader in blood glucose monitoring, serving more than 20 million people with diabetes. Ms. Asbury previously held a series of leadership roles within Johnson & Johnson (NYSE:JNJ) for over 20 years from 1998 to 2018, including executive sales and general management positions. Her most recent position at Johnson & Johnson was Global President of Diabetes Solutions from 2013 to 2018, including the Global LifeScan subsidiary until its sale in October 2018 to Platinum Equity, a leading private investment firm. She holds a Bachelor of Science in Nursing from Vanderbilt University.

    Brent Shafer most recently served as Chairman and CEO of Cerner Corporation from 2018 until September 2021, a global healthcare technology company that was acquired by Oracle Corporation (NYSE:ORCL) in December 2021. Prior to Cerner, Mr. Shafer was Chief Executive Officer of Philips North America, a health technology company and the North American division of Koninklijke Philips N.V. (("Philips", NYSE:PHG, AEX: PHIA)), from 2014 to 2018. Mr. Shafer also served as Chief Executive Officer of the global Philips' Home Healthcare Solutions business from 2010 until 2014. Mr. Shafer previously held a series of leadership roles at Philips, Hill Rom and GE Healthcare. He holds a Bachelor of Science from the University of Utah.

    About Tactile Medical

    Tactile Medical is a leader in developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease by helping them live better and care for themselves at home. The company collaborates with clinicians to expand clinical evidence, raise awareness, increase access to care, reduce overall healthcare costs and improve the quality of life for tens of thousands of patients each year.  



    Investor Inquiries:
    Mike Piccinino, CFA
    Managing Director
    ICR Westwicke
    [email protected]

    Primary Logo

    Get the next $JNJ alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $JNJ
    $ORCL
    $PHG
    $TCMD

    CompanyDatePrice TargetRatingAnalyst
    Oracle Corporation
    $ORCL
    12/3/2025$280.00Overweight
    Wells Fargo
    Johnson & Johnson
    $JNJ
    11/13/2025$230.00Sector Outperform
    Scotiabank
    Oracle Corporation
    $ORCL
    11/10/2025Buy → Hold
    Erste Group
    Tactile Systems Technology Inc.
    $TCMD
    11/4/2025$28.00Neutral → Buy
    BTIG Research
    Johnson & Johnson
    $JNJ
    10/20/2025$203.00Neutral → Outperform
    Daiwa Securities
    Oracle Corporation
    $ORCL
    10/13/2025$345.00 → $355.00Outperform
    BMO Capital Markets
    Oracle Corporation
    $ORCL
    10/9/2025$365.00Outperform
    Robert W. Baird
    Tactile Systems Technology Inc.
    $TCMD
    10/3/2025$23.50Buy
    Lake Street
    More analyst ratings

    $JNJ
    $ORCL
    $PHG
    $TCMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Johnson & Johnson to Participate in the 44th Annual J.P. Morgan Healthcare Conference

    Johnson & Johnson (NYSE:JNJ) will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12th, 2026. Management will participate in a Fireside Chat at 11:15 a.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnson's Investor Relations website at www.investor.jnj.com. An archived edition of the session will be available later that day. The audio webcast replay will be available approximately 48 hours after the webcast. View source version on businesswire.com: https://www.businesswire.com/news/home/20251208077091/en/ Media contact: [email protected] Investor contact: [email protected]

    12/8/25 4:25:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson's INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC

    New data from Cohort 4 of the SunRISe-1 study show more than 95 percent of patients remained progression free at one year, with more than 92 percent not undergoing bladder removal Patients with this type of bladder cancer have limited choices beyond radical cystectomy, highlighting the need for newer therapies for bladder preservation RARITAN, N.J., Dec. 5, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today that new data from the investigational Cohort 4 of the Phase 2b SunRISe-1 study show treatment with gemcitabine intravesical system resulted in high one-year disease-free survival (DFS), progression-free survival (PFS), and overall survival (OS) rates in patients with Bacil

    12/5/25 4:20:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Philips reiterates timing of 2026 outlook

    December 4, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, today reaffirmed that its 2026 outlook will be issued as planned on February 10, in line with the company's previously communicated schedule. As previously guided, the company expects continued performance improvement with sequential comparable sales growth, expanded margins (despite tariff headwinds) and strong cashflow. The company continues to expect comparative sales growth to accelerate sequentially in 2026 towards mid-single-digit growth in line with the current trajectory and supported by continued solid order momentum. This is in line with performance in the las

    12/4/25 7:14:25 AM ET
    $PHG
    Medical Electronics
    Health Care

    $JNJ
    $ORCL
    $PHG
    $TCMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Chief Accounting Officer Smith Maria converted options into 11,016 shares and covered exercise/tax liability with 5,740 shares, increasing direct ownership by 11% to 52,359 units (SEC Form 4)

    4 - ORACLE CORP (0001341439) (Issuer)

    12/9/25 7:12:19 PM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    SEC Form 4 filed by Johnson & Johnson

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    12/1/25 4:15:39 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Johnson & Johnson sold $27,132 worth of shares (2,700 units at $10.05) (SEC Form 4)

    4 - JOHNSON & JOHNSON (0000200406) (Reporting)

    11/25/25 12:54:13 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $ORCL
    $PHG
    $TCMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fairhead Rona Alison bought $112,258 worth of shares (480 units at $233.87), increasing direct ownership by 2% to 22,110 units (SEC Form 4)

    4 - ORACLE CORP (0001341439) (Issuer)

    7/9/25 4:39:51 PM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    Director Boskin Michael J bought $111,145 worth of shares (1,682 units at $66.08), increasing direct ownership by 2% to 92,458 units (SEC Form 4)

    4 - ORACLE CORP (0001341439) (Issuer)

    3/21/25 8:43:30 PM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    Director Moorman Charles W bought $947,913 worth of shares (5,500 units at $172.35) (SEC Form 4)

    4 - ORACLE CORP (0001341439) (Issuer)

    2/14/25 4:41:16 PM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    $JNJ
    $ORCL
    $PHG
    $TCMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo initiated coverage on Oracle with a new price target

    Wells Fargo initiated coverage of Oracle with a rating of Overweight and set a new price target of $280.00

    12/3/25 8:40:00 AM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    Scotiabank initiated coverage on Johnson & Johnson with a new price target

    Scotiabank initiated coverage of Johnson & Johnson with a rating of Sector Outperform and set a new price target of $230.00

    11/13/25 9:14:21 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oracle downgraded by Erste Group

    Erste Group downgraded Oracle from Buy to Hold

    11/10/25 9:51:17 AM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    $JNJ
    $ORCL
    $PHG
    $TCMD
    SEC Filings

    View All

    SEC Form 8-K filed by Oracle Corporation

    8-K - ORACLE CORP (0001341439) (Filer)

    11/21/25 4:26:49 PM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    SEC Form 13F-HR filed by Johnson & Johnson

    13F-HR - JOHNSON & JOHNSON (0000200406) (Filer)

    11/13/25 3:25:42 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Koninklijke Philips N.V. NY Registry Shares

    6-K - KONINKLIJKE PHILIPS NV (0000313216) (Filer)

    11/4/25 10:55:41 AM ET
    $PHG
    Medical Electronics
    Health Care

    $JNJ
    $ORCL
    $PHG
    $TCMD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    July 21, 2023 - FDA Roundup: July 21, 2023

    For Immediate Release: July 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA Center for Tobacco Products (CTP) announced that the center will host a virtual listening session on Aug. 22, 2023. During this listening session, CTP is requesting feedback on the development of a new 5-year strategic plan for the center, includin

    7/21/23 4:02:23 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    May 5, 2022 - Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals

    For Immediate Release: May 05, 2022 Today, the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not

    5/5/22 4:51:11 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    August 18, 2021 - Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots

    For Immediate Release: August 18, 2021 Today, public health and medical experts from the U.S. Department of Health and Human Services (HHS) released the following statement on the Administration’s plan for COVID-19 booster shots for the American people. The statement is attributable to Dr. Rochelle Walensky, Director of the Centers for Disease Control and Prevention (CDC); Dr. Janet Woodcock, Acting Commissione

    8/18/21 1:06:11 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $ORCL
    $PHG
    $TCMD
    Leadership Updates

    Live Leadership Updates

    View All

    Health Systems Simplify Secure Data Exchange with Oracle Health

    New Oracle Health Connection Hub delivers single, unified console to enable data sharing control, auditing, and governance so health systems can easily manage a broad range of interoperability services Early adopters see 50 percent reduction in processing times of Social Security Administration disability benefit claims AUSTIN, Texas, Oct. 9, 2025 /PRNewswire/ -- Oracle Health Connection Hub is now generally available for U.S. healthcare providers, enabling them to use a single console to more easily onboard, access, and manage preferences for Oracle Health interoperability solutions. The latest step in Oracle's strategy to increase interoperability and reduce friction between payers and pr

    10/9/25 9:00:00 AM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    Vicarious Surgical Announces Appointment of Joseph Doherty as Chairman of The Board

    Vicarious Surgical Inc. (NYSE:RBOT, RBOT.WS)) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the appointment of Joseph Doherty as Chairman of the Company's Board of Directors (the "Board"). Mr. Doherty has served as a member of the Board since June 2025. "Since joining Vicarious Surgical, I've had the opportunity to work closely with Joe and greatly value his perspective," said Stephen From, Chief Executive Officer. "As Chairman of the Board, he brings a wealth of experience and thoughtful leadership that will serve the Company well. I look forward to partnering with him and the Board as we advance o

    9/25/25 4:15:00 PM ET
    $JNJ
    $RBOT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties

    Johnson & Johnson Elects John Morikis, Retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, to its Board of Directors

    Johnson & Johnson (NYSE:JNJ) announced today that John Morikis, retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, has been elected to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250908666514/en/John Morikis headshot "We are pleased to welcome John to our Company's Board of Directors," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "He is a proven leader of a large multinational organization who possesses a strong understanding of global markets and complex supply chains. His unique perspective and ability to harness technology to driv

    9/8/25 6:17:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $ORCL
    $PHG
    $TCMD
    Financials

    Live finance-specific insights

    View All

    Oracle Sets the Date for its Second Quarter Fiscal Year 2026 Earnings Announcement

    Earnings Results to be released on December 10, 2025, After the Close of the Market AUSTIN, Texas, Dec. 2, 2025 /PRNewswire/ -- Oracle Corporation today announced that its second quarter fiscal year 2026 results will be released on Wednesday, December 10th, after the close of the market.  Oracle will host a conference call and live webcast at 4:00 p.m. Central Time to discuss the financial results.  The live webcast will be available on the Oracle Investor Relations website at www.oracle.com/investor.  About Oracle Oracle offers integrated suites of applications plus secure, a

    12/2/25 8:00:00 AM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    Philips continues momentum; delivers strong order intake, step-up in sales growth and margin expansion

    November 4, 2025Q3 2025 Group Highlights Comparable order intake growth 8%Group sales amounted to EUR 4.3 billion, reflecting 3% increase in comparable salesIncome from operations was EUR 330 millionAdjusted EBITA margin increased by 50 basis points to 12.3% of salesOperating cash flow of EUR 327 million, with a free cash flow of EUR 172 millionPhilips reiterates full-year 2025 outlook, with margin now expected at the upper end of the range Roy Jakobs, CEO of Royal Philips:"In this quarter we maintained our momentum, with AI-powered innovations and long-term partnerships making a real difference for patients and consumers. We drove strong order intake and accelerated sales growth, with sus

    11/4/25 1:00:00 AM ET
    $PHG
    Medical Electronics
    Health Care

    Tactile Systems Technology, Inc. Reports Third Quarter 2025 Financial Results

    MINNEAPOLIS, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the third quarter ended September 30, 2025 and announced the adoption of a second share repurchase program. Third Quarter 2025 Summary & Recent Business Highlights: Total revenue increased 17% year-over-year to $85.8 millionGross margin of 76% versus 75% in Q3 2024Net income of $8.2 million versus $5.2 million in Q3 2024Adjusted EBITDA of $14.4 million versus $10.7 million in Q3 2024Announced six-month data demonstrating sustained benefits o

    11/3/25 4:05:00 PM ET
    $TCMD
    Medical/Dental Instruments
    Health Care

    $JNJ
    $ORCL
    $PHG
    $TCMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Tactile Systems Technology Inc.

    SC 13G/A - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)

    11/13/24 7:29:11 PM ET
    $TCMD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Tactile Systems Technology Inc.

    SC 13G - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)

    11/13/24 5:04:27 PM ET
    $TCMD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Tactile Systems Technology Inc.

    SC 13G - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)

    11/8/24 3:21:42 PM ET
    $TCMD
    Medical/Dental Instruments
    Health Care